Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company based in Boston, Massachusetts, specializing in the development and commercialization of innovative therapies derived from novel tetracycline chemistry. The company’s lead product, NUZYRA, is a broad-spectrum antibiotic administered in both oral and intravenous forms, targeting adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Another significant product, SEYSARA, is designed for the treatment of moderate to severe acne vulgaris. Paratek has received Qualified Infectious Disease Product designation from the U.S. Food and Drug Administration for its lead antibiotic, reflecting its commitment to addressing urgent public health threats, including antibiotic resistance. The company maintains various collaboration agreements, including partnerships with Zai Lab and Allergan, as well as research agreements with academic institutions and military organizations, to further its mission in combating infectious diseases and exploring additional therapeutic areas such as multiple sclerosis and systemic inflammatory diseases.
OptiNose
Acquisition in 2025
OptiNose is a specialty pharmaceutical company that specializes in nasal drug delivery technologies and innovative combination drug/device therapies. The company has developed a unique and patent-protected Bi-Directional Delivery system, which enhances the efficiency of drug deposition in the upper posterior regions of the nasal cavity, surpassing the limitations of traditional delivery devices. OptiNose's products, including the XHANCE nasal spray, utilize this proprietary technology to deliver medications effectively to the primary site of inflammation, particularly in conditions such as chronic rhinosinusitis with nasal polyps. Clinical trials have demonstrated that these devices not only provide a faster onset of action but also achieve greater therapeutic effects with lower doses and fewer side effects. OptiNose operates offices in Norway and the UK, focusing on advancing the treatment options available to patients under the care of ear, nose, and throat, and allergy specialists.
Transcept Pharmaceuticals
Acquisition in 2014
Transcept Pharmaceuticals, Inc. uses its proprietary delivery system to enhance the penetration of drugs, significantly speeding their onset of action. Transcept is developing rapid-acting versions of several major market pharmaceuticals. Hamilton co-invested in the company's first institutional round of funding alongside Montreaux Equity Partners, Peninsula Equity Partners and Vivo Ventures. Investors in subsequent financing rounds include these firms, and New Leaf Venture Partners, Interwest Partners and New Enterprise Associates.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.